Peter Welford
Stock Analyst at Jefferies
(1.59)
# 2,239
Out of 4,413 analysts
8
Total ratings
66.67%
Success rate
12.06%
Average return
Main Sectors:
Top Industries:
4 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AZN AstraZeneca | Downgrades: Hold | n/a | $75.88 | - | 4 | Jan 3, 2024 | |
| GSK GSK | Upgrades: Buy | $39 → $48 | $41.44 | +15.83% | 1 | Jan 3, 2024 | |
| GLPG Galapagos NV | Upgrades: Hold | $49 → $47 | $28.45 | +65.91% | 2 | Jan 23, 2023 | |
| GMAB Genmab | Downgrades: Hold | n/a | $27.69 | - | 1 | Sep 16, 2021 |
AstraZeneca
Jan 3, 2024
Downgrades: Hold
Price Target: n/a
Current: $75.88
Upside: -
GSK
Jan 3, 2024
Upgrades: Buy
Price Target: $39 → $48
Current: $41.44
Upside: +15.83%
Galapagos NV
Jan 23, 2023
Upgrades: Hold
Price Target: $49 → $47
Current: $28.45
Upside: +65.91%
Genmab
Sep 16, 2021
Downgrades: Hold
Price Target: n/a
Current: $27.69
Upside: -